What is Cadrenal Therapeutics, Inc. Common Stock (CVKD) stock price today?

Cadrenal Therapeutics, Inc. Common Stock (CVKD) currently trades at $6.67 per share. The stock has a market capitalization of $13.79M and a P/E ratio of —x.

Is CVKD stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Cadrenal Therapeutics, Inc. Common Stock has a Smart Value Score of 16/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -5.40.

Is Cadrenal Therapeutics, Inc. Common Stock financially healthy?

Cadrenal Therapeutics, Inc. Common Stock's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -5.40 places it in the distress.

CVKD

Cadrenal Therapeutics, Inc. Common Stock

NASDAQ: CVKD · HEALTHCARE · BIOTECHNOLOGY

$6.67

+19.32% today

Updated 2026-04-30

Market cap

$13.79M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-6.64

Dividend yield

—

52W range

$4 – $17

Volume

0.1M

Market cap

$13.79M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-6.64

Dividend yield

—

52W range

$4 – $17

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.8

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-5.4

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$27.67

+314.84%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -5.40 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-2.57M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	—	$0.00	$0.00	$0.00	$0.00
Net income	$-6.71M	$-8.36M	$-10.65M	$-13.24M	$-3.04M
EPS	—	—	—	—	$-6.64
Free cash flow	$-1.21M	$-3.53M	$-7.36M	$-12.61M	$-2.57M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CVKD	$13.79M	16	4.3	3.0	5.0	4.8	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Cadrenal Therapeutics, Inc. Common Stock trades at $6.67. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -5.40, it sits in the distress.

Frequently asked questions

What is Cadrenal Therapeutics, Inc. Common Stock's stock price?

Cadrenal Therapeutics, Inc. Common Stock (CVKD) trades at $6.67.

Is Cadrenal Therapeutics, Inc. Common Stock overvalued?

Smart Value Score 16/100 (Grade F, Strong Sell).

What is the price target of Cadrenal Therapeutics, Inc. Common Stock (CVKD)?

The analyst target price is $27.67, representing +314.8% upside from the current price of $6.67.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-5.40 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.cadrenal.com

Quick metrics

P/S ratio—

ROE-260.10%

Beta1.55

50D MA$6.24

200D MA$9.77

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

CVKD vs LLY →CVKD vs JNJ →CVKD vs ABBV →Stock screener →